Safety and Efficacy Evaluation of IM19 CAR-T Cells (IM19CAR-T)

Assessment of the Safety and Feasibility of Administering T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor to Patients With CD19+ B-cell leukemia and determine the best dosage.

Inclusion criteria

• Patients with CD19+ Refractory or Relapsed B-ALL（At least 2 prior combination chemotherapy regimens）
• To be aged 3 to 75 years
• Blast in blood ≤ 30%
• ECOG score ≤2
• Women of childbearing potential must have a urine pregnancy test taken and proven negative prior to the treatment. All patients agree to use reliable methods of contraception during the trial period and until follow-up for the last time.
• Voluntary participation in the clinical trials and sign the informed consent.

Exclusion criteria

• Intracranial hypertension or unconsciousness
• Respiratory failure
• CD19 negative
• Disseminated intravascular coagulation
• ALT /AST>3 x normal value; Creatinine> 1.5 x normal value; Bilirubin >2.0 x normal value
• Hematosepsis or Uncontrolled active infection
• Uncontrolled diabetes
• Abalienation;
• WHO Sscore >3
• Patients in pregnancy or breast-feeding period
• Previously treatment with any gene therapy products
• Any uncontrolled medical disorders that the researchers consider are not eligible to participate the clinical trial
• Any situation that would increase dangerousness of subjects or disturb the outcome of the clinical study according to the researcher's evaluation.